Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets.
Level 5 - mechanism / opinion, no new human data
Animal research (preclinical animal experiment)
PubMed 15507655 · doi:10.1128/JVI.78.22.12672-12676.2004
What was done
Ferrets (Mustela putorius furo) were immunized with recombinant modified vaccinia virus Ankara (rMVA) expressing the SARS-CoV spike (S) protein. Following vaccination, animals were challenged with SARS-CoV to evaluate neutralizing antibody kinetics and histopathological liver inflammation relative to control animals.
What was found
The abstract does not report numerical data. Following SARS-CoV challenge, immunized ferrets exhibited a more rapid and vigorous neutralizing antibody response than controls, but also developed strong inflammatory responses in liver tissue. Control animals exposed to SARS-CoV exhibited only mild liver inflammation.
Why it matters
This paper identifies potential vaccine-associated immunopathology and disease enhancement in a coronavirus model, highlighting the critical need for safety monitoring in spike-directed vaccine candidates.
Limits
The findings are from a preclinical ferret model and cannot be directly extrapolated to humans. The abstract does not state the sample size (n), quantitative antibody titers, specific histological scores, or underlying cellular mechanisms mediating the enhanced liver inflammation.
Cited by
- supports Vaccine candidates developed for SARS-CoV-1 in 2002-2003 caused antibody-dependent enhancement in some animal studies.